-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
-
Cosmetic Ingredient
- Water Treatment Chemical
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
A few days ago, CG Oncology announced the preliminary results of phase 2 clinical trials of its oncolytic virus therapy CG0070, in combination with the heavy anti-PD-1 antibody Keytruda, in the treatment of non-muscular invasive bladder cancer.
Oncolytic virus is a type of virus that can selectively lyse cancer cells.
CG0070 is based on a modified adenovirus type 5 (Ad5) backbone, including a tumor-specific promoter, and a granulocyte-macrophage colony stimulating factor (GM-CSF) transgene
Preliminary clinical trial results showed that as of November 8, 2021, 100% of patients who reached the 3-month assessment point (n=9) had a complete remission, and among the patients who reached the 6-month assessment point (n=6), All patients maintained complete remission, and the complete remission rate of patients who reached the 9-month assessment point was still 100% (n=3)
In terms of safety, treatment-related adverse events were limited to temporary grade 1-2 local urogenital symptoms and immune-related adverse events, and no treatment-related adverse events or serious adverse events above grade 3 were found
Reference materials:
[1] CG Oncology Presents Preliminary Phase 2 Data with CG0070 in Combination with KEYTRUDA® (pembrolizumab) in Non-Muscle-Invasive Bladder Cancer Unresponsive to Bacillus Calmette-Guerin.
(The original text has been deleted)
